Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

clinical benefit

This page shows the latest clinical benefit news and features for those working in and with pharma, biotech and healthcare.

ICER says Alnylam’s Onpattro should cost 90%-95% less

ICER says Alnylam’s Onpattro should cost 90%-95% less

its price would have to be reduced 90%-95% to come into line with the benefit to patients. ... However, ICER goes on to say that there “may be uncertainties related to the translation of neurologic outcomes to longer-term clinical benefit, the

Latest news

  • Biogen and Eisai claim mid-stage win for Alzheimer’s drug Biogen and Eisai claim mid-stage win for Alzheimer’s drug

    They estimate– based on Eisai’s earlier communications on the drug and trial design – that the clinical benefit could be around 20-25% and “certainly very clinically meaningful”if so.

  • ICER says price of Amgen/Novartis’ Aimovig is OK - if used last-line ICER says price of Amgen/Novartis’ Aimovig is OK - if used last-line

    Novartis and Amgen’s decision to price their new migraine drug Aimovig lower than expected seems to have paid off, with US pricing watchdog ICER concluding that it matches the clinical ... ICER (the Institute for Clinical and Economic Review) estimates

  • Safety scuppers combo trials with J&J/Genmab’s Darzalex Safety scuppers combo trials with J&J/Genmab’s Darzalex

    There was a “numerical increase”in deaths when Darzalex was added to Tecentriq and no evidence of any increase in clinical benefit compared to Tecentriq on its own in the LUC2001 ... We are pleased that the development program for daratumumab remains

  • Daily Brief Daily Brief

    The company has a second drug, cancer candidate Clevegen, a novel anti-Clever-1 antibody, which enters clinical trials later this year. ... They say the algorithm takes into account the actual costs of R&D, manufacturing, sales, marketing and a fair

  • Another IO knockback as Tecentriq combo fails phase III trial Another IO knockback as Tecentriq combo fails phase III trial

    cancer (CRC) showed no benefit on overall survival compared to Bayer’s Stivarga (regorafenib), a drug typically used in that hard-to-treat population. ... The results from IMblaze370 were consistent with this prior monotherapy experience, showing that

More from news
Approximately 1 fully matching, plus 153 partially matching documents found.

Latest Intelligence

  • The European Medicines Agency: PRIME’d for access? The European Medicines Agency: PRIME’d for access?

    The scheme. The PRIME scheme is for medicines that have real promise, defined by the EMA as medicines that may offer a major therapeutic advantage over existing treatments, or benefit patients ... Companies who want to benefit from the scheme have to

  • Can new data aggregators shift the balance of power away from pharma? Can new data aggregators shift the balance of power away from pharma?

    This could have far-reaching consequences for some players in the pharmaceutical industry who may find their product pricing to be untenable when the cost/clinical benefit calculus becomes totally transparent.

  • Patient recruitment and engagement standards Patient recruitment and engagement standards

    And the reality: 50% of clinical research sites don’t recruit a single patient. ... A number of studies have revealed that awareness changes patients’perceptions about clinical trials, enrolment and the risk/benefit ratio of getting involved.

  • Taking a lean and careful approach Taking a lean and careful approach

    Chemotherapy and Pharmacology, which concluded its treatment regimen showed ‘encouraging clinical benefit’. ... Clinical trials. The company is moving cautiously and set its clinical trials in Israel, Italy, Turkey and Greece.

  • Strengthening market access deliverables by harnessing the patient journey Strengthening market access deliverables by harnessing the patient journey

    Topics such as the clinical value of new products, or what impact the product has on outcomes are relevant to multiple stakeholders. ... management, clinical benefit and economic/humanistic benefit.

More from intelligence
Approximately 0 fully matching, plus 23 partially matching documents found.

Latest appointments

  • Dr Irina Antonijevic joins vasopharm Dr Irina Antonijevic joins vasopharm

    In this role, Dr Antonijevic will be responsible for advancing the clinical development of the cerebrovascular specialist's lead orphan drug candidate, VAS203. ... Not only will we benefit from her clinical capabilities in our ongoing pivotal study of

  • ICON's CEO named chair of ACRO ICON's CEO named chair of ACRO

    ICON's CEO named chair of ACRO. Trade body for clinical research organisation elects Ciaran Murray. ... I look forward to continuing the work that ACRO has done in promoting our industry as one that conducts safe, ethical and high-quality clinical

  • Industry veteran Louis Nisbet joins Sygnature board Industry veteran Louis Nisbet joins Sygnature board

    The UK-based clinical research organisation (CRO) will benefit from Dr Nisbet's extensive experience in the life sciences industry, which includes spells in research at Roche, Glaxo and SmithKline.

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • Irritable Bowel Syndrome (IBS) Patient Insights

    Irritable bowel syndrome in adults: diagnosis and management. NICE Clinical Guideline 61; 2017. ... International survey of patients with IBS: Symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit.

  • Why and how doctors should be involved in startups

    provide useful clinical insight that can benefit a startup.

  • Immunotherapy in oncology

    These three states align with the clinical observations of response, stable disease and progression of disease. ... However, the group recognised that delayed responses and prolonged stable disease were having a significant survival benefit, underscoring

  • What will the NHS’s Capped Expenditure Process (CEP) mean for pharma?

    Balancing doctors’ demands for drugs that demonstrate strong clinical benefit and patient safety against medicines management teams’ focus on cost savings will be critical in CEP areas. ... In such areas, bringing together multi-disciplinary networks

  • How will the NHS’s new medicines savings drive affect pharma?

    Engagement tactics must balance clinicians’ demand for products that show strong clinical benefit and patient safety against medicines management teams’ focus on the cost savings that can be generated by specific ... full benefit of expensive drugs,

More from PMHub
Approximately 0 fully matching, plus 11 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Quick links

Infographics

Multimedia